Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
{{output}}
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used to treat patients with type 2 diabetes since 2005 and have become popular because of the efficacy and durability in relation to glycaemic control in combination with weight loss in most patie... ...